Amgen Reports Positive Phase 3 Results for Dazodalibep
Amgen announced positive Phase 3 results for dazodalibep in Sjögren's disease.
Related stories
Jasmine International Reports Quarterly Attributable Loss of 723 Million Baht
M impact | EQUITY | Nov 11, 2026, 03:13 PM UTC
BBVA Plans EUR 1 Billion Convertible Preferred Share Issue
BBVA plans to issue EUR 1 billion in unregistered convertible preferred shares.
M impact | EQUITY | Nov 11, 2026, 03:09 PM UTC
Zinzino Acquires Uzesta Assets to Expand APAC Distribution
Zinzino acquired rights to Uzesta’s distributor database, customer records, inventory and intellectual property through subsidiaries in Taiwan, Hong Kong and Thailand.
M impact | EQUITY | Nov 11, 2026, 03:05 PM UTC
Nasdaq Gains 1.6% as Nvidia Jumps 5% in Tech-Led Rebound
Wall Street rose Wednesday, with the Nasdaq Composite gaining 1.6% and the S&P 500 advancing nearly 1%. Nvidia rebounded after two sessions of losses; CoreWeave rallied after bette
M impact | EQUITY | Nov 11, 2026, 03:01 PM UTC
US session market picture: S&P 500 +0.83%, Nasdaq 100 +1.62%; EUR/USD -0.71%, WTI +1.91%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.83 percent, Nasdaq futures is up 1.62 percent, Dow futures is down 0.06 percent and Russell futures is up 0.7 p
M impact | EQUITY | Nov 11, 2026, 03:00 PM UTC
CoreWeave Rallies About 12% After Earnings Ease AI-Buildout Worries
CoreWeave shares rose about 12% after its earnings eased investor concerns about AI infrastructure spending. The stock was the Nasdaq-100’s second most actively traded name that mo
M impact | EQUITY | Nov 11, 2026, 02:57 PM UTC